{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "09", "@year": "2020", "@timestamp": "2020-01-09T06:26:31.000031-05:00", "@month": "01"}, "ait:date-sort": {"@day": "01", "@year": "2015", "@month": "12"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Graduate School"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "113152181"}, "@dptid": "113152181"}, "author": [{"ce:given-name": "Naruemol", "preferred-name": {"ce:given-name": "Naruemol", "ce:initials": "N.", "ce:surname": "Angsirisak", "ce:indexed-name": "Angsirisak N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:degrees": "M.Sc", "ce:surname": "Angsirisak", "@auid": "57057844000", "ce:indexed-name": "Angsirisak N."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Pharmacology"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "104425668"}, "@dptid": "104425668"}, "author": [{"ce:given-name": "Supeecha", "preferred-name": {"ce:given-name": "Supeecha", "ce:initials": "S.", "ce:surname": "Wittayalertpanya", "ce:indexed-name": "Wittayalertpanya S."}, "@seq": "2", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:degrees": "M.Sc", "ce:surname": "Wittayalertpanya", "@auid": "6602827304", "ce:indexed-name": "Wittayalertpanya S."}, {"ce:given-name": "Wacharee", "preferred-name": {"ce:given-name": "Wacharee", "ce:initials": "W.", "ce:surname": "Limpanasithikul", "ce:indexed-name": "Limpanasithikul W."}, "@seq": "3", "ce:initials": "W.", "@_fa": "true", "@type": "auth", "ce:degrees": "Ph.D.", "ce:surname": "Limpanasithikul", "@auid": "6602707697", "ce:indexed-name": "Limpanasithikul W."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "113019942"}, "@dptid": "113019942"}, "author": [{"ce:given-name": "Udomsak", "preferred-name": {"ce:given-name": "Udomsak", "ce:initials": "U.", "ce:surname": "Bunworasate", "ce:indexed-name": "Bunworasate U."}, "@seq": "4", "ce:initials": "U.", "@_fa": "true", "@type": "auth", "ce:degrees": "Ph.D.", "ce:surname": "Bunworasate", "@auid": "6507403499", "ce:indexed-name": "Bunworasate U."}, {"ce:given-name": "Danai", "preferred-name": {"ce:given-name": "Danai", "ce:initials": "D.", "ce:surname": "Owattanapanich", "ce:indexed-name": "Owattanapanich D."}, "@seq": "5", "ce:initials": "D.", "@_fa": "true", "@type": "auth", "ce:degrees": "Ph.D.", "ce:surname": "Owattanapanich", "@auid": "57057871900", "ce:indexed-name": "Owattanapanich D."}]}], "citation-title": "Correlation of Fc\u03b3RIIIa polymorphisms to the response of rituximab in Thai patients with diffuse large B-cell lymphoma", "abstracts": "\u00a9 2015, Medical Association of Thailand. All rights reserved.Background: Rituximab is an anti-CD20 chimeric antibody widely used in combination with CHOP regimen for the treatment of diffuse large B-cell lymphoma (DLBCL). It is suggested that this antibody destroys B lymphoma cells mainly by antibody dependent cellular cytotoxicity (ADCC) mechanism via the binding of the drug to FC gamma IIIa receptor (Fc\u03b3RIIIa) on natural killer (NK) cells, affected to kill cancer cells. The Fc\u03b3RIIIa has genetic polymorphism at nucleotide position 559 (G559T or V158F or rs396991) have shown influence on the binding and efficacy of rituximab. Objective: We identified the distribution of Fc\u03b3RIIIa polymorphism in Thai patients with DLBCL and investigated the correlation between Fc\u03b3RIIIa polymorphisms and the clinical outcomes in Thai DLBCL patients who were treated with rituximab plus CHOP chemotherapy regimen. Material and Method: The Taqman SNP real-time PCR assay was used to identify the Fc\u03b3RIIIa polymorphism in the present study and the clinical outcomes of these patients were evaluated and correlated between Fc\u03b3RIIIa polymorphism. Results: The distribution of Fc\u03b3RIIIa genotype in patients were 54.17% homozygous V/V, 10.41% homozygous F/F, and 35.42% heterozygous V/F, and there was no differences in clinical response among these patients (p-value = 0.31). Complete response was assessed in V/V 84.62%, V/F 88.24%, and F/F 80.00%. Partial response was in V/V 7.68% and F/F 20.00%. Stable disease was in V/F 11.76%, progressive disease in V/V 7.72%. Conclusion: The correlation could not be found between Fc\u03b3RIIIa polymorphisms to the response of rituximab in Thai patients with diffuse large B-cell lymphoma.", "correspondence": {"affiliation": {"country": "Thailand", "postal-code": "10330", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Pharmacology"}, {"$": "Chulalongkorn University"}]}, "person": {"ce:given-name": "Supeecha", "ce:initials": "S.", "ce:degrees": "M.Sc", "ce:surname": "Wittayalertpanya", "ce:indexed-name": "Wittayalertpanya S."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "Anti CD20", "@xml:lang": "eng"}, {"$": "Diffuse large B-cell lymphoma", "@xml:lang": "eng"}, {"$": "Fc\u03b3RIIIa polymorphism", "@xml:lang": "eng"}, {"$": "Rituximab", "@xml:lang": "eng"}]}, "citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": [{"@language": "English", "@xml:lang": "eng"}, {"@language": "Thai", "@xml:lang": "tha"}]}, "source": {"website": {"ce:e-address": {"$": "http://www.jmatonline.com/index.php/jmat/article/viewfile/6715/6449", "@type": "email"}}, "translated-sourcetitle": {"$": "Journal of the Medical Association of Thailand", "@xml:lang": "eng"}, "volisspag": {"voliss": {"@volume": "98", "@issue": "12"}, "pagerange": {"@first": "1215", "@last": "1221"}}, "@type": "j", "sourcetitle": "Journal of the Medical Association of Thailand", "publicationdate": {"month": "12", "year": "2015", "date-text": "December 2015", "day": "01"}, "codencode": "JMTHB", "sourcetitle-abbrev": "J. Med. Assoc. Thailand", "@country": "tha", "issn": {"$": "01252208", "@type": "print"}, "publicationyear": {"@first": "2015"}, "publisher": {"publishername": "Medical Association of Thailand", "ce:e-address": {"$": "math@loxinfo.co.th", "@type": "email"}}, "@srcid": "17780"}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "EMCLASS", "classification": [{"classification-code": "16", "classification-description": "Cancer"}, {"classification-code": "22", "classification-description": "Human Genetics"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}]}, {"@type": "ASJC", "classification": "2700"}, {"@type": "SUBJABBR", "classification": "MEDI"}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": "50-18-0", "chemical-name": "cyclophosphamide"}, {"cas-registry-number": [{"$": "23214-92-8"}, {"$": "25316-40-9"}], "chemical-name": "doxorubicin"}, {"cas-registry-number": "53-03-2", "chemical-name": "prednisone"}, {"cas-registry-number": "174722-31-7", "chemical-name": "rituximab"}, {"cas-registry-number": "57-22-7", "chemical-name": "vincristine"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Antineoplastic Agents"}, {"chemical-name": "FCGR3A protein, human"}, {"chemical-name": "Receptors, IgG"}, {"chemical-name": "Rituximab"}]}]}}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "EMBASE"}, {"$": "REAXYSCAR"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}, {"$": "MEDL"}], "history": {"date-created": {"@day": "01", "@year": "2016", "@timestamp": "BST 20:46:27", "@month": "04"}}, "itemidlist": {"itemid": [{"$": "607786172", "@idtype": "PUI"}, {"$": "644379014", "@idtype": "CAR-ID"}, {"$": "20160049527", "@idtype": "EMBASE"}, {"$": "2016263358", "@idtype": "REAXYSCAR"}, {"$": "84954310160", "@idtype": "SCP"}, {"$": "84954310160", "@idtype": "SGR"}, {"$": "611464089", "@idtype": "PUIsecondary"}, {"$": "27004307", "@idtype": "MEDL"}]}}, "tail": {"bibliography": {"@refcount": "22", "reference": [{"ref-fulltext": "Intragumtornchai T, Wannakrairoj P, Chaimongkol B, Bhoopat L, Lekhakula A, Thamprasit T, et al. Non-Hodgkin's lymphomas in Thailand. A retrospective pathologic and clinical analysis of 1391 cases. Cancer 1996; 78: 1813-9.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "1996"}, "ref-title": {"ref-titletext": "Non-Hodgkin's lymphomas in Thailand. A retrospective pathologic and clinical analysis of 1391 cases"}, "refd-itemidlist": {"itemid": {"$": "10144247291", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "78"}, "pagerange": {"@first": "1813", "@last": "1819"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Intragumtornchai", "ce:indexed-name": "Intragumtornchai T."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Wannakrairoj", "ce:indexed-name": "Wannakrairoj P."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Chaimongkol", "ce:indexed-name": "Chaimongkol B."}, {"@seq": "4", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Bhoopat", "ce:indexed-name": "Bhoopat L."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Lekhakula", "ce:indexed-name": "Lekhakula A."}, {"@seq": "6", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Thamprasit", "ce:indexed-name": "Thamprasit T."}], "et-al": null}, "ref-sourcetitle": "Cancer"}}, {"ref-fulltext": "Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-32.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications"}, "refd-itemidlist": {"itemid": {"$": "79955961315", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "117"}, "pagerange": {"@first": "5019", "@last": "5032"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Campo", "ce:indexed-name": "Campo E."}, {"@seq": "2", "ce:initials": "S.H.", "@_fa": "true", "ce:surname": "Swerdlow", "ce:indexed-name": "Swerdlow S.H."}, {"@seq": "3", "ce:initials": "N.L.", "@_fa": "true", "ce:surname": "Harris", "ce:indexed-name": "Harris N.L."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Pileri", "ce:indexed-name": "Pileri S."}, {"@seq": "5", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Stein", "ce:indexed-name": "Stein H."}, {"@seq": "6", "ce:initials": "E.S.", "@_fa": "true", "ce:surname": "Jaffe", "ce:indexed-name": "Jaffe E.S."}]}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 1988; 85: 208-12.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "1988"}, "ref-title": {"ref-titletext": "Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes"}, "refd-itemidlist": {"itemid": {"$": "0023672444", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "85"}, "pagerange": {"@first": "208", "@last": "212"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.F.", "@_fa": "true", "ce:surname": "Tedder", "ce:indexed-name": "Tedder T.F."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Streuli", "ce:indexed-name": "Streuli M."}, {"@seq": "3", "ce:initials": "S.F.", "@_fa": "true", "ce:surname": "Schlossman", "ce:indexed-name": "Schlossman S.F."}, {"@seq": "4", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Saito", "ce:indexed-name": "Saito H."}]}, "ref-sourcetitle": "Proc Natl Acad Sci U S A"}}, {"ref-fulltext": "Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998; 6: 195-7.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "1998"}, "ref-title": {"ref-titletext": "Rituximab: A new therapeutic monoclonal antibody for non-Hodgkin's lymphoma"}, "refd-itemidlist": {"itemid": {"$": "0031957306", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6"}, "pagerange": {"@first": "195", "@last": "197"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.D.", "@_fa": "true", "ce:surname": "Scott", "ce:indexed-name": "Scott S.D."}]}, "ref-sourcetitle": "Cancer Pract"}}, {"ref-fulltext": "Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107: 176-82.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "CD20-mediated apoptosis: Signalling through lipid rafts"}, "refd-itemidlist": {"itemid": {"$": "0036408912", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "107"}, "pagerange": {"@first": "176", "@last": "182"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.P.", "@_fa": "true", "ce:surname": "Deans", "ce:indexed-name": "Deans J.P."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Li", "ce:indexed-name": "Li H."}, {"@seq": "3", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Polyak", "ce:indexed-name": "Polyak M.J."}]}, "ref-sourcetitle": "Immunology"}}, {"ref-fulltext": "Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359: 613-26.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma"}, "refd-itemidlist": {"itemid": {"$": "49349095724", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "359"}, "pagerange": {"@first": "613", "@last": "626"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.D.", "@_fa": "true", "ce:surname": "Cheson", "ce:indexed-name": "Cheson B.D."}, {"@seq": "2", "ce:initials": "J.P.", "@_fa": "true", "ce:surname": "Leonard", "ce:indexed-name": "Leonard J.P."}]}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949-54.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas"}, "refd-itemidlist": {"itemid": {"$": "0037306893", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "101"}, "pagerange": {"@first": "949", "@last": "954"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Manches", "ce:indexed-name": "Manches O."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Lui", "ce:indexed-name": "Lui G."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Chaperot", "ce:indexed-name": "Chaperot L."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Gressin", "ce:indexed-name": "Gressin R."}, {"@seq": "5", "ce:initials": "J.P.", "@_fa": "true", "ce:surname": "Molens", "ce:indexed-name": "Molens J.P."}, {"@seq": "6", "ce:initials": "M.C.", "@_fa": "true", "ce:surname": "Jacob", "ce:indexed-name": "Jacob M.C."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentrationeffect relationship. Cancer Res 2004; 64: 4664-9.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentrationeffect relationship"}, "refd-itemidlist": {"itemid": {"$": "3042743884", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "64"}, "pagerange": {"@first": "4664", "@last": "4669"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Dall'Ozzo", "ce:indexed-name": "Dall'Ozzo S."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Tartas", "ce:indexed-name": "Tartas S."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Paintaud", "ce:indexed-name": "Paintaud G."}, {"@seq": "4", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Cartron", "ce:indexed-name": "Cartron G."}, {"@seq": "5", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Colombat", "ce:indexed-name": "Colombat P."}, {"@seq": "6", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bardos", "ce:indexed-name": "Bardos P."}], "et-al": null}, "ref-sourcetitle": "Cancer Res"}}, {"ref-fulltext": "Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2000"}, "ref-title": {"ref-titletext": "Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets"}, "refd-itemidlist": {"itemid": {"$": "0034076307", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6"}, "pagerange": {"@first": "443", "@last": "446"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.A.", "@_fa": "true", "ce:surname": "Clynes", "ce:indexed-name": "Clynes R.A."}, {"@seq": "2", "ce:initials": "T.L.", "@_fa": "true", "ce:surname": "Towers", "ce:indexed-name": "Towers T.L."}, {"@seq": "3", "ce:initials": "L.G.", "@_fa": "true", "ce:surname": "Presta", "ce:indexed-name": "Presta L.G."}, {"@seq": "4", "ce:initials": "J.V.", "@_fa": "true", "ce:surname": "Ravetch", "ce:indexed-name": "Ravetch J.V."}]}, "ref-sourcetitle": "Nat Med"}}, {"ref-fulltext": "Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-8.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene"}, "refd-itemidlist": {"itemid": {"$": "0036464719", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "99"}, "pagerange": {"@first": "754", "@last": "758"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Cartron", "ce:indexed-name": "Cartron G."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Dacheux", "ce:indexed-name": "Dacheux L."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Salles", "ce:indexed-name": "Salles G."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Solal-Celigny", "ce:indexed-name": "Solal-Celigny P."}, {"@seq": "5", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bardos", "ce:indexed-name": "Bardos P."}, {"@seq": "6", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Colombat", "ce:indexed-name": "Colombat P."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-68.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance"}, "refd-itemidlist": {"itemid": {"$": "0642312825", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "22"}, "pagerange": {"@first": "7359", "@last": "7368"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.R.", "@_fa": "true", "ce:surname": "Smith", "ce:indexed-name": "Smith M.R."}]}, "ref-sourcetitle": "Oncogene"}}, {"ref-fulltext": "Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006; 108: 2720-5.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma"}, "refd-itemidlist": {"itemid": {"$": "33750618232", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "108"}, "pagerange": {"@first": "2720", "@last": "2725"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.H.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim D.H."}, {"@seq": "2", "ce:initials": "H.D.", "@_fa": "true", "ce:surname": "Jung", "ce:indexed-name": "Jung H.D."}, {"@seq": "3", "ce:initials": "J.G.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim J.G."}, {"@seq": "4", "ce:initials": "J.J.", "@_fa": "true", "ce:surname": "Lee", "ce:indexed-name": "Lee J.J."}, {"@seq": "5", "ce:initials": "D.H.", "@_fa": "true", "ce:surname": "Yang", "ce:indexed-name": "Yang D.H."}, {"@seq": "6", "ce:initials": "Y.H.", "@_fa": "true", "ce:surname": "Park", "ce:indexed-name": "Park Y.H."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Mitrovic Z, Aurer I, Radman I, Ajdukovic R, Sertic J, Labar B. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 2007; 92: 998-9.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma"}, "refd-itemidlist": {"itemid": {"$": "34548710218", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "92"}, "pagerange": {"@first": "998", "@last": "999"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Z.", "@_fa": "true", "ce:surname": "Mitrovic", "ce:indexed-name": "Mitrovic Z."}, {"@seq": "2", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Aurer", "ce:indexed-name": "Aurer I."}, {"@seq": "3", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Radman", "ce:indexed-name": "Radman I."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Ajdukovic", "ce:indexed-name": "Ajdukovic R."}, {"@seq": "5", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Sertic", "ce:indexed-name": "Sertic J."}, {"@seq": "6", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Labar", "ce:indexed-name": "Labar B."}]}, "ref-sourcetitle": "Haematologica"}}, {"ref-fulltext": "Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22: 4717-24.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype"}, "refd-itemidlist": {"itemid": {"$": "14544301233", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "22"}, "pagerange": {"@first": "4717", "@last": "4724"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.K.", "@_fa": "true", "ce:surname": "Weng", "ce:indexed-name": "Weng W.K."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Czerwinski", "ce:indexed-name": "Czerwinski D."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Timmerman", "ce:indexed-name": "Timmerman J."}, {"@seq": "4", "ce:initials": "F.J.", "@_fa": "true", "ce:surname": "Hsu", "ce:indexed-name": "Hsu F.J."}, {"@seq": "5", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Levy", "ce:indexed-name": "Levy R."}]}, "ref-sourcetitle": "J Clin Oncol"}}, {"ref-fulltext": "Torkildsen O, Utsi E, Mellgren SI, Harbo HF, Vedeler CA, Myhr KM. Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology 2005; 115: 416-21.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations"}, "refd-itemidlist": {"itemid": {"$": "21244498647", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "115"}, "pagerange": {"@first": "416", "@last": "421"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Torkildsen", "ce:indexed-name": "Torkildsen O."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Utsi", "ce:indexed-name": "Utsi E."}, {"@seq": "3", "ce:initials": "S.I.", "@_fa": "true", "ce:surname": "Mellgren", "ce:indexed-name": "Mellgren S.I."}, {"@seq": "4", "ce:initials": "H.F.", "@_fa": "true", "ce:surname": "Harbo", "ce:indexed-name": "Harbo H.F."}, {"@seq": "5", "ce:initials": "C.A.", "@_fa": "true", "ce:surname": "Vedeler", "ce:indexed-name": "Vedeler C.A."}, {"@seq": "6", "ce:initials": "K.M.", "@_fa": "true", "ce:surname": "Myhr", "ce:indexed-name": "Myhr K.M."}]}, "ref-sourcetitle": "Immunology"}}, {"ref-fulltext": "Weng WK, Weng WK, Levy R. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma 2009; 50: 1494-500.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma"}, "refd-itemidlist": {"itemid": {"$": "78649910862", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "50"}, "pagerange": {"@first": "1494", "@last": "1500"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.K.", "@_fa": "true", "ce:surname": "Weng", "ce:indexed-name": "Weng W.K."}, {"@seq": "2", "ce:initials": "W.K.", "@_fa": "true", "ce:surname": "Weng", "ce:indexed-name": "Weng W.K."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Levy", "ce:indexed-name": "Levy R."}]}, "ref-sourcetitle": "Leuk Lymphoma"}}, {"ref-fulltext": "Somboonyosdech C, Wittayalertpunya S, Bunworasate U, Limpanasithikul W. Correlation of FcgammaRIIIa polymorphisms and the response to rituximab in Thai population. Asian Biomed 2012; 6: 883-9.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Correlation of FcgammaRIIIa polymorphisms and the response to rituximab in Thai population"}, "refd-itemidlist": {"itemid": {"$": "84874644171", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6"}, "pagerange": {"@first": "883", "@last": "889"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Somboonyosdech", "ce:indexed-name": "Somboonyosdech C."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Wittayalertpunya", "ce:indexed-name": "Wittayalertpunya S."}, {"@seq": "3", "ce:initials": "U.", "@_fa": "true", "ce:surname": "Bunworasate", "ce:indexed-name": "Bunworasate U."}, {"@seq": "4", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Limpanasithikul", "ce:indexed-name": "Limpanasithikul W."}]}, "ref-sourcetitle": "Asian Biomed"}}, {"ref-fulltext": "Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 1472-4.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia"}, "refd-itemidlist": {"itemid": {"$": "0842264005", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "103"}, "pagerange": {"@first": "1472", "@last": "1474"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.S.", "@_fa": "true", "ce:surname": "Farag", "ce:indexed-name": "Farag S.S."}, {"@seq": "2", "ce:initials": "I.W.", "@_fa": "true", "ce:surname": "Flinn", "ce:indexed-name": "Flinn I.W."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Modali", "ce:indexed-name": "Modali R."}, {"@seq": "4", "ce:initials": "T.A.", "@_fa": "true", "ce:surname": "Lehman", "ce:indexed-name": "Lehman T.A."}, {"@seq": "5", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Young", "ce:indexed-name": "Young D."}, {"@seq": "6", "ce:initials": "J.C.", "@_fa": "true", "ce:surname": "Byrd", "ce:indexed-name": "Byrd J.C."}]}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007; 92: 1127-30.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab"}, "refd-itemidlist": {"itemid": {"$": "35748951343", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "92"}, "pagerange": {"@first": "1127", "@last": "1130"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Carlotti", "ce:indexed-name": "Carlotti E."}, {"@seq": "2", "ce:initials": "G.A.", "@_fa": "true", "ce:surname": "Palumbo", "ce:indexed-name": "Palumbo G.A."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Oldani", "ce:indexed-name": "Oldani E."}, {"@seq": "4", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Tibullo", "ce:indexed-name": "Tibullo D."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Salmoiraghi", "ce:indexed-name": "Salmoiraghi S."}, {"@seq": "6", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Rossi", "ce:indexed-name": "Rossi A."}], "et-al": null}, "ref-sourcetitle": "Haematologica"}}, {"ref-fulltext": "Zhang W, Wang X, Li J, Duan MH, Zhou DB. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. Chin Med J (Engl) 2010; 123: 198-202.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma"}, "refd-itemidlist": {"itemid": {"$": "76549122287", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "123"}, "pagerange": {"@first": "198", "@last": "202"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Zhang", "ce:indexed-name": "Zhang W."}, {"@seq": "2", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Wang", "ce:indexed-name": "Wang X."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Li", "ce:indexed-name": "Li J."}, {"@seq": "4", "ce:initials": "M.H.", "@_fa": "true", "ce:surname": "Duan", "ce:indexed-name": "Duan M.H."}, {"@seq": "5", "ce:initials": "D.B.", "@_fa": "true", "ce:surname": "Zhou", "ce:indexed-name": "Zhou D.B."}]}, "ref-sourcetitle": "Chin Med J (Engl)"}}, {"ref-fulltext": "Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Revised response criteria for malignant lymphoma"}, "refd-itemidlist": {"itemid": {"$": "33947496614", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "25"}, "pagerange": {"@first": "579", "@last": "586"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.D.", "@_fa": "true", "ce:surname": "Cheson", "ce:indexed-name": "Cheson B.D."}, {"@seq": "2", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Pfistner", "ce:indexed-name": "Pfistner B."}, {"@seq": "3", "ce:initials": "M.E.", "@_fa": "true", "ce:surname": "Juweid", "ce:indexed-name": "Juweid M.E."}, {"@seq": "4", "ce:initials": "R.D.", "@_fa": "true", "ce:surname": "Gascoyne", "ce:indexed-name": "Gascoyne R.D."}, {"@seq": "5", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Specht", "ce:indexed-name": "Specht L."}, {"@seq": "6", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Horning", "ce:indexed-name": "Horning S.J."}], "et-al": null}, "ref-sourcetitle": "J Clin Oncol"}}, {"ref-fulltext": "Wang WL, Zhang GL, Wu LH, Yao MY, Jin J, Jia CK, et al. Efficacy of hepatitis B immunoglobulin in relation to the gene polymorphisms of human leukocyte Fcgamma receptor III (CD16) in Chinese liver transplant patients. Chin Med J (Engl) 2007; 120: 1606-10.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Efficacy of hepatitis B immunoglobulin in relation to the gene polymorphisms of human leukocyte Fcgamma receptor III (CD16) in Chinese liver transplant patients"}, "refd-itemidlist": {"itemid": {"$": "35349030395", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "120"}, "pagerange": {"@first": "1606", "@last": "1610"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.L.", "@_fa": "true", "ce:surname": "Wang", "ce:indexed-name": "Wang W.L."}, {"@seq": "2", "ce:initials": "G.L.", "@_fa": "true", "ce:surname": "Zhang", "ce:indexed-name": "Zhang G.L."}, {"@seq": "3", "ce:initials": "L.H.", "@_fa": "true", "ce:surname": "Wu", "ce:indexed-name": "Wu L.H."}, {"@seq": "4", "ce:initials": "M.Y.", "@_fa": "true", "ce:surname": "Yao", "ce:indexed-name": "Yao M.Y."}, {"@seq": "5", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Jin", "ce:indexed-name": "Jin J."}, {"@seq": "6", "ce:initials": "C.K.", "@_fa": "true", "ce:surname": "Jia", "ce:indexed-name": "Jia C.K."}], "et-al": null}, "ref-sourcetitle": "Chin Med J (Engl)"}}]}}}}, "affiliation": {"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, "coredata": {"srctype": "j", "eid": "2-s2.0-84954310160", "dc:description": "Background: Rituximab is an anti-CD20 chimeric antibody widely used in combination with CHOP regimen for the treatment of diffuse large B-cell lymphoma (DLBCL). It is suggested that this antibody destroys B lymphoma cells mainly by antibody dependent cellular cytotoxicity (ADCC) mechanism via the binding of the drug to FC gamma IIIa receptor (Fc\u03b3RIIIa) on natural killer (NK) cells, affected to kill cancer cells. The Fc\u03b3RIIIa has genetic polymorphism at nucleotide position 559 (G559T or V158F or rs396991) have shown influence on the binding and efficacy of rituximab. Objective: We identified the distribution of Fc\u03b3RIIIa polymorphism in Thai patients with DLBCL and investigated the correlation between Fc\u03b3RIIIa polymorphisms and the clinical outcomes in Thai DLBCL patients who were treated with rituximab plus CHOP chemotherapy regimen. Material and Method: The Taqman SNP real-time PCR assay was used to identify the Fc\u03b3RIIIa polymorphism in the present study and the clinical outcomes of these patients were evaluated and correlated between Fc\u03b3RIIIa polymorphism. Results: The distribution of Fc\u03b3RIIIa genotype in patients were 54.17% homozygous V/V, 10.41% homozygous F/F, and 35.42% heterozygous V/F, and there was no differences in clinical response among these patients (p-value = 0.31). Complete response was assessed in V/V 84.62%, V/F 88.24%, and F/F 80.00%. Partial response was in V/V 7.68% and F/F 20.00%. Stable disease was in V/F 11.76%, progressive disease in V/V 7.72%. Conclusion: The correlation could not be found between Fc\u03b3RIIIa polymorphisms to the response of rituximab in Thai patients with diffuse large B-cell lymphoma.", "pubmed-id": "27004307", "prism:coverDate": "2015-12-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/84954310160", "dc:creator": {"author": [{"ce:given-name": "Naruemol", "preferred-name": {"ce:given-name": "Naruemol", "ce:initials": "N.", "ce:surname": "Angsirisak", "ce:indexed-name": "Angsirisak N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "M.Sc", "ce:surname": "Angsirisak", "@auid": "57057844000", "author-url": "https://api.elsevier.com/content/author/author_id/57057844000", "ce:indexed-name": "Angsirisak N."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/84954310160"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84954310160&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84954310160&origin=inward"}], "source-id": "17780", "citedby-count": "2", "prism:volume": "98", "subtype": "ar", "dc:title": "Correlation of Fc\u03b3RIIIa polymorphisms to the response of rituximab in Thai patients with diffuse large B-cell lymphoma", "openaccess": null, "prism:issn": "01252208", "publishercopyright": "\u00a9 2015, Medical Association of Thailand. All rights reserved.", "prism:issueIdentifier": "12", "subtypeDescription": "Article", "prism:publicationName": "Journal of the Medical Association of Thailand", "prism:pageRange": "1215-1221", "prism:endingPage": "1221", "openaccessFlag": null, "prism:startingPage": "1215", "dc:identifier": "SCOPUS_ID:84954310160", "dc:publisher": "Medical Association of Thailandmath@loxinfo.co.th"}, "idxterms": {"mainterm": [{"$": "Antibody-Dependent Cell Cytotoxicity", "@weight": "b", "@candidate": "n"}, {"$": "Antineoplastic Agents", "@weight": "b", "@candidate": "n"}, {"$": "Antineoplastic Combined Chemotherapy Protocols", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "Genotype", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Killer Cells, Natural", "@weight": "b", "@candidate": "n"}, {"$": "Lymphoma, Large B-Cell, Diffuse", "@weight": "a", "@candidate": "n"}, {"$": "Male", "@weight": "b", "@candidate": "n"}, {"$": "Middle Aged", "@weight": "b", "@candidate": "n"}, {"$": "Neoplasm Staging", "@weight": "b", "@candidate": "n"}, {"$": "Pharmacogenetics", "@weight": "b", "@candidate": "n"}, {"$": "Polymorphism, Genetic", "@weight": "b", "@candidate": "n"}, {"$": "Receptors, IgG", "@weight": "b", "@candidate": "n"}, {"$": "Rituximab", "@weight": "b", "@candidate": "n"}, {"$": "Statistics as Topic", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "Anti CD20"}, {"@_fa": "true", "$": "Diffuse large B-cell lymphoma"}, {"@_fa": "true", "$": "Fc\u03b3RIIIa polymorphism"}, {"@_fa": "true", "$": "Rituximab"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Medicine (all)", "@code": "2700", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Naruemol", "preferred-name": {"ce:given-name": "Naruemol", "ce:initials": "N.", "ce:surname": "Angsirisak", "ce:indexed-name": "Angsirisak N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "M.Sc", "ce:surname": "Angsirisak", "@auid": "57057844000", "author-url": "https://api.elsevier.com/content/author/author_id/57057844000", "ce:indexed-name": "Angsirisak N."}, {"ce:given-name": "Supeecha", "preferred-name": {"ce:given-name": "Supeecha", "ce:initials": "S.", "ce:surname": "Wittayalertpanya", "ce:indexed-name": "Wittayalertpanya S."}, "@seq": "2", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "M.Sc", "ce:surname": "Wittayalertpanya", "@auid": "6602827304", "author-url": "https://api.elsevier.com/content/author/author_id/6602827304", "ce:indexed-name": "Wittayalertpanya S."}, {"ce:given-name": "Wacharee", "preferred-name": {"ce:given-name": "Wacharee", "ce:initials": "W.", "ce:surname": "Limpanasithikul", "ce:indexed-name": "Limpanasithikul W."}, "@seq": "3", "ce:initials": "W.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "Ph.D.", "ce:surname": "Limpanasithikul", "@auid": "6602707697", "author-url": "https://api.elsevier.com/content/author/author_id/6602707697", "ce:indexed-name": "Limpanasithikul W."}, {"ce:given-name": "Udomsak", "preferred-name": {"ce:given-name": "Udomsak", "ce:initials": "U.", "ce:surname": "Bunworasate", "ce:indexed-name": "Bunworasate U."}, "@seq": "4", "ce:initials": "U.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "Ph.D.", "ce:surname": "Bunworasate", "@auid": "6507403499", "author-url": "https://api.elsevier.com/content/author/author_id/6507403499", "ce:indexed-name": "Bunworasate U."}, {"ce:given-name": "Danai", "preferred-name": {"ce:given-name": "Danai", "ce:initials": "D.", "ce:surname": "Owattanapanich", "ce:indexed-name": "Owattanapanich D."}, "@seq": "5", "ce:initials": "D.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "Ph.D.", "ce:surname": "Owattanapanich", "@auid": "57057871900", "author-url": "https://api.elsevier.com/content/author/author_id/57057871900", "ce:indexed-name": "Owattanapanich D."}]}}}